Telomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical Type 2 Diabetes Model

About this update from Telomir Pharmaceuticals, Inc.

Insulin Resistance Was Normalized Following 14 Days of Treatment, Supporting Restoration of Glucose Metabolism and Insulin Sensitivity and Further Validating Telomir-Zn's Metal-Homeostasis Mechanism Across Multiple Disease Models. MIAMI, FL / ACCESS Newswire / June 15, 2026 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer and age-related disease, today announced the peer-reviewed publication of preclinical data demonstrating restoration of insulin sensitivity and significant improvement in glucose homeostasis with Telomir-Zn in a diet-induced zebrafish model of Type 2 diabetes mellitus (T2DM).The manuscript, titled "Telomir-Zn Restores Glucose Homeostasis and Reduces Insulin Resistance in a Diet-Induced Zebrafish Model of Type 2 Diabetes," has been published in Biomedicine & Pharmacotherapy.The publication is available online in Biomedicine & Pharmacotherapy.Publication HighlightsType 2 diabetes mellitus is characterized by chronic hyperglycemia, impaired glucose utilization, and insulin resistance. Insulin resistance is a central driver of disease progression and is associated with oxidative stress, mitochondrial dysfunction, and metabolic dysregulation.In the study, zebrafish fed a high-calorie diet developed significant metabolic dysfunction, including fasting hyperglycemia, hyperinsulinemia, impaired glucose tolerance, and HOMA-IR values of approximately 10-12, consistent with severe insulin resistance.According to the publication, treatment with Telomir-Zn produced dose-dependent improvements across multiple independent measures of metabolic health, including:Significant reduction in fasting blood glucose levels to near control levelsImproved glucose clearance during oral glucose tolerance testing (OGTT)Reduction in fasting insulin concentrationsSignificant improvement in HOMA-IR, a widely used measure of insulin resistanceMost notably, HOMA-IR values declined from approximately 10-12 in untreated diabetic animals to approximately 3 following 14 days of treatment, representing a substantial reversal of insulin resistance. Improvements were observed in a dose-dependent manner and remained consistent across both Day 7 and Day 14 assessments.The authors concluded that Telomir-Zn restored key metabo...

View stock analysis, news, and events for Telomir Pharmaceuticals, Inc.